CAAS Capital Management’s Eli Lilly LLY Stock Holding History

CAAS Capital Management’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$3.72M	Buy	4,500 +2,200	+96%	+$1.83M	0.4%	55
2024 Q4	$1.78M	Sell	2,300 -5,400	-70%	-$4.47M	0.31%	68
2024 Q3	$6.82M	Buy	+7,700	New	+$6.92M	0.8%	35
2022 Q4	–	Sell	-12,900	Closed	-$4.17M	–	878
2022 Q3	$4.17M	Buy	+12,900	New	+$4.09M	0.2%	155
2022 Q2	–	Sell	-25,000	Closed	-$7.16M	–	968
2022 Q1	$7.16M	Buy	+25,000	New	+$6.43M	0.29%	103
2021 Q4	–	Sell	-200,000	Closed	-$46.2M	–	962
2021 Q3	$46.2M	Buy	+200,000	New	+$49.4M	0.93%	16
2021 Q2	–	Sell	-33,300	Closed	-$6.22M	–	1171
2021 Q1	$6.22M	Buy	33,300 +31,800	+2,120%	+$6.22M	0.07%	310
2020 Q4	$253K	Hold	1,500	–	–	﹤0.01%	745
2020 Q3	$222K	Sell	1,500 -36,000	-96%	-$5.57M	0.01%	435
2020 Q2	$6.16M	Buy	37,500 +27,900	+291%	+$4.28M	0.2%	117
2020 Q1	$1.33M	Buy	+9,600	New	+$1.32M	0.14%	120

Other funds holding LLY

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

CAAS Capital Management's LLY Position: Q1 2025 in Review

CAAS Capital Management reduced its Eli Lilly (LLY) stake by 31% in Q1 2025, selling an estimated $631K and leaving 1,650 shares worth $1.36M. The position accounts for 0.15% of the portfolio, ranked #146.

CAAS Capital Management first reported a position in LLY in Q1 2020 and has held it in 8 quarters since. The position peaked at $4.27M in Q1 2021. 3,919 funds tracked by Wall St. Rank hold LLY as of Q1 2025.

CAAS Capital Management held 1,650 shares of Eli Lilly worth $1.36M as of Q1 2025.
CAAS Capital Management sold 758 Eli Lilly shares in Q1 2025, an estimated $631K.
Eli Lilly made up 0.15% of CAAS Capital Management's portfolio in Q1 2025, its #146 holding.
CAAS Capital Management first reported a position in Eli Lilly in Q1 2020 and has held it in 8 quarters since.
CAAS Capital Management's Eli Lilly position peaked at $4.27M in Q1 2021.
3,919 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2025.

Based on CAAS Capital Management's 13F filing for Q1 2025, filed 1 May 2025.